Mecasermin Tercica

Current Opinion in Investigational Drugs

Volumn 7, Issue 4, 2006, Pages 371-380

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BENZYL ALCOHOL; DES(1-3)SOMATOMEDIN C; DEXAMETHASONE; GROWTH HORMONE; GROWTH HORMONE ANTIBODY; HUMAN GROWTH HORMONE; INCRELEX; INSULIN; MICROSPHERE; MKC 031; MKN 031; NEUTRALIZING ANTIBODY; PHENOL; POLYGLACTIN; POLYSORBATE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SODIUM CHLORIDE; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN C[LEUCINE 3 ARGININE]; SOMAZON; STREPTOZOCIN; UNCLASSIFIED DRUG;

ADRENAL MEDULLA TUMOR; ANTIBODY PRODUCTION; BREAST CARCINOMA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG PURITY; DRUG RELEASE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENCAPSULATION; GENE DELETION; GROWTH DISORDER; HEARING DISORDER; HUMAN; HYPOGLYCEMIA; INJECTION SITE HYPERTROPHY; LARON SYNDROME; LIPOHYPERTROPHY; NONHUMAN; PEDIATRICS; PHARYNX DISEASE; PROTEIN DEFICIENCY; REVIEW; SNORING; STRUCTURE ACTIVITY RELATION; SUSTAINED RELEASE FORMULATION; TONSIL DISEASE; TOXICITY TESTING; TYMPANOMETRY;

ANIMALS; BODY WEIGHT; CLINICAL TRIALS; DIABETES MELLITUS; GROWTH; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645776473     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. 9 Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice. Gillespie C, Read LC, Bagley CJ, Ballard FJ J ENDOCRINOL 1990 127 3 401-405
2. 8 Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ J ENDOCRINOL 1991 128 1 97-105
3. 3 IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection. Lemmey AB, Martin AA, Read LC, Tomas FM, Owens PC, Ballard FJ AM J PHYSIOL 1991 260 2 Pt 1 E213-E219
4. 84 IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass. Martin AA, Tomas FM, Owens PC, Knowles SE, Ballard FJ, Read LC AM J PHYSIOL 1991 261 4 Pt 2 F626-633
5. 85 Truncated and native insulin like growth factor I enhance mucosal adaptation after jejunoileal resection. Vanderhoof JA, McCusker RH, Clark R, Mohammadpour H, Blackwood DJ, Harty RF, Park JHY GASTROENTEROLOGY 1992 102 6 1949-1956
6. 90 Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats. Read LC, Tomas FM, Howarth GS, Martin AA, Edson KJ, Gillespie CM, Owens PC. Ballard FJ J ENDOCRINOL 1992 133 3 421-431
7. 83 Phase I study of insulin like growth factor-1 (IGF-1) in HIV. Sattler F, Dube M, Montgomery AB, Lopresti J, Leedom J, Nicolof J ICAAC 1994 34 Abs I12
8. 86 A randomized, double blind placebo-controlled phase II trial of growth hormone and insuline-like growth factor I for AIDS wasting. Foster K, Nightingale S, Gesundheit N, Waters D, Bukar J, Qualls C, Danska J, Watson D, Jackson L, Hardy K, Schade D ICAAC 1994 34 Abs I10
9. 12 Large scale, in situ isolation of periplasmic IGF-I from E coli. Hart RA, Lester PM, Reifsnyder DH, Ogez JR, Builder SE BIOTECHNOLOGY 1994 12 11 1113-1116
10. 80 Nikken Chemical Co Ltd: Annual Report. Nikken Chemical Co Ltd ANNUAL REPORT 1993 December 13
11. 53 Genentech Inc: Annual Report. Genentech Inc ANNUAL REPORT 1994 December 31
12. 19 A monthly review of what to happening in R&D. PHARM MARKETING 1995 7 7 42-43
13. 51 Genentech discontinues IGF-1 drug development effort in type I and II diabetes - research of IGF-I in other therapeutic areas continues. Genentech Inc PRESS RELEASE 1997 September 05
14. 37 The obese growth hormone (GH)-efficient dwarf rat: Body fat responses to patterned delivery of GH and insulin-like growth factor-I. Clark RG, Mortensen DL, Carlsson LM, Carlsson B, Carmignac D, Robinson IC ENDOCRINOLOGY 1996 137 5 1904-1912
15. 88 Cephalon and Chiron withdraw application to market Myotrophin in Europe. Cephalon Inc PRESS RELEASE 1998 September 15
16. 63 Insulin-like growth factor binding protein-1 induces insulin release in the rat. Mortensen DL, Won WB, Siu J, Reifsnyder D, Gironella M, Etcheverry T, Clark RG ENDOCRINOLOGY 1997 138 5 2073-2080
17. 66 Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG ENDOCRINOLOGY 1996 137 5 1913-1920
18. 56 Recombinant human insulin-like growth factor I (rhIGF-I) can improve insulin sensitivity and glycemic control in patients with the type B syndrome of severe insulin resistance. Gabbay RA, O'Brien M, Moses AC ANN MEET AM DIABETES ASSOC 1999 59 Abs 0049
19. 62 Drug development pipeline: IGF-1, NGF. Genentech Inc COMPANY COMMUNICATION 2001 January 30
20. 37 Chiron Corp: Form 10-K. Chiron Corp FORM 10-K 2001 December 31
21. 93 Genentech licenses IGF-I to Tercica Medica Inc. Genentech Inc PRESS RELEASE 2002 May 23
22. 79 Tercica licenses patent rights to rhIGF-1 from Fujisawa in extreme insulin resistance. Tercica Inc PRESS RELEASE 2004 April 29
23. 97 Tercica makes payment to Genentech for rights to IGF-1 combined with IGFBP-3. Tercica Inc PRESS RELEASE 2004 June 15
24. 77 Tercica submits marketing authorization application for Increlex in the European Union. Tercica Inc PRESS RELEASE 2005 December 07
25. 25 Tercica launches Increlex in the US; only drug approved for the long-term treatment of growth failure caused by severe primary IGFD. Tercica Inc PRESS RELEASE 2006 January 03
26. 10 Recombinant human IGF-1 prevents type 1 diabetes in female non-obese diabetic mice. Liu F, Yu M, Zhu Q ZHONGHUA YU FANG YI XUE ZA ZHI 2000 34 5 281-283
27. 11 Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL J CONTROL RELEASE 2000 67 2-3 281-292
28. 12 Metabolism and degradation products of recombinant human insuline-like growth factor-I in lysosomes of rat kidney. Tanaka Y, Tamoto H, Tozuka Z, Sato A, Kimura T XENOBIOTICA 1999 29 3 281-295
29. 13 Effect of recombinant human insulin-like growth factor-I on expression of glucose transporters, GLUT 2 and GLUT 4, in streptozotocin-diabetic rat. Asada T, Ogawa T, Iwai M, Kobayashi M JPN J PHARMACOL 1998 78 1 63-67
30. 14 Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-assiociated wasting. A randomized, double-blind, placebo-controlled trial. Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D, Nightingale S, Gesundheit N, Watson D, Schade D ANN INTERN MED 1996 125 11 885-872
31. 15 Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. Ellis KJ, Lee PD, Pivarnik JM, Bukar JG, Gesundheit N J CLIN ENDOCRINOL METAB 1996 81 8 3033-3038
32. 16 A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. Lee PD, Pivarnik JM, Bukar JG, Muurahainen N, Berry PS, Skolnik PR, Nerad JL, Kudsk KA, Jackson L, Ellis KJ, Gesundheit N J CLIN ENDOCRINOL METAB 1996 81 8 2968-2975
33. 17 Three year IGF-I treatment of children with Laron syndrome. Klinger B, Laron Z J PEDIATR ENDOCRINOL METAB 1995 8 3 149-158
34. 19 Chemical heterogeneity as a result of hydroxylamine cleavage of a fusion protein of human insulin-like growth factor I. Canova-Davis E, Eng M, Mukku V, Reifsnyder DH, Olson CV, Ling VT BIOCHEM J 1992 285 1 207-213
35. 20 Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ BIOCHEM J 1991 276 2 547-554
36. 20 Life-long high dose rhIGP-1 in the rat: A reduction in endocrine cancers. Clark RG ANN MEET ENDOCRINE SOC 2005 87 Abs P2-670
37. 25 Long-term therapy wtth rhIGF-1: No evidence of neutralizing antibodies. Clark R, Frane J, Bright G ANN MEET ENDOCRINE SOC 2005 87 Abs P1-493
38. 26 IGFBP-3 is increased by acute and chronic rhIGF-1 injections in humans. Bright G, Guevara-Aguirre J, Rosenfeld R, Liao S, Clark R ANN MEET ENDOCRINE SOC 2005 87 Abs OR43-1
39. 54 Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Ballard FJ BIOCHEM J 291 3 781-786
40. 55 Effects of insulin-like growth factors on protein metabolism: Why are some molecular variants more potent? Ballard FJ, Francis GL, Bagley CJ, Szabo L, Wallace JC BIOCHEM SOC SYMP 1989 55 91-104
41. 40 Package Insert - Increlex (mecasermin, Tercica Inc). Tercica Inc DRUG PACKAGE INSERT 2005 August 1-2
42. 59 Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: Biological activities and receptor binding. Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC BIOCHEM BIOPHYS RES COMMUN 1987 149 2 398-404
43. 90 Patient selection for IGF-I therapy. Clayton PE, Ayoola O, Whatmore AJ HORM RES 2006 65 Suppl 1 28-34
44. 03 Efficacy of rhIGF-1 in the treatment of children with IGF-1 deficiency (IGFD) due to GH insensitivity (GHIS): 274 treatment years. Chernausek S, Frane J, Bright G, Underwood L, The GHIS Collaborative Group EUROPEAN SOCIETY FOR PEDIATRIC ENDOCRINOLOGY/LAWSON WILKINS PEDIATRIC ENDOCRINE SOCIETY 7TH JOINT MEETING 2005 Abs P2-574
45. 57 Efficacy of long-term treatment with recombinant human IGF-1 in children wtth GH insensitivity. Underwood L, Chernausek SD, Kuntze J, Frane J, Bright GM, GHIS Collaborative Study Group ANN MEET ENDOCRINE SOC 2004 86 Abs P3-450.
46. 12 Safety of recombinant human insulin-like growth factor-1 (rhIGF-1) in the treatment of children wtth IGF-1 deficiency (IGFD) due to GH insensitivity: 231 Treatment-years of experience. Duncan V, Horn JA ANN CONVENTION PEDIATR ENDOCRINOL NURS SOC 2005 18 Abs
47. 18 Treatment of short stature wtth recombinant human IGF-1. Duncan V, Horn JA ANN CONVENTION PEDIATR ENDOCRINOL NURS SOC 2005 18 Abs
48. 69 Safety of recombinant human IGF-1 in the treatment of children with IGF-1 deficiency due to GH insensitivity: 231 Treatment-years of experience. Chernausek SD, Underwood L, Kuntze J, Frane J, Bright GM, GHIS Collaborative Study Group ANN MEET ENDOCRINE SOC 2004 86 Abs P3-451
49. 70 Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Baxter RC AM J PHYSIOL ENDOCRINOL METAB 2000 278 6 E967-E976
50. 72 The essential role of IGF-I: Lessons from the long-term study and treatment of children and adults with Laron syndrome. Laron Z J CLIN ENDOCRINOL METAB 1999 84 12 4397-4404
51. 73 Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: A systematic review. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, Peto J, Silva Idos S CANCER EPIDEMIOL BIOMARKERS PREV 2005 14 1 2-19
52. 74 Insulin, insulin-like growth factors and colon cancer: A review of the evidence. Giovannucci E J NUTR 2001 131 11 Suppl 3109S-3120S
53. 75 Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes. Henry RR CLIN THER 2003 25 Suppl B B47-B63
54. 90 Laron-type dwarfism (hereditary somatomedin deficiency): A review. Laron Z ERGEB IN MED KINDERHEILKD 1984 51 117-150